 Connection
David Simpson to Muscle Spasticity
This is a "connection" page, showing publications David Simpson has written about Muscle Spasticity.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
8.485 |
|
|
|
-
Wissel J, Cam?es-Barbosa A, Comes G, Althaus M, Scheschonka A, Simpson DM. Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis. Toxins (Basel). 2021 Dec 11; 13(12).
Score: 0.742
-
Bensmail D, Wissel J, Laffont I, Simon O, Scheschonka A, Flatau-Baqu? B, Dressler D, Simpson DM. Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus. Ann Phys Rehabil Med. 2021 Mar; 64(2):101376.
Score: 0.661
-
Wissel J, Bensmail D, Scheschonka A, Flatau-Baqu? B, Simon O, Althaus M, Simpson DM. Post hoc analysis of the improvement in shoulder spasticity and safety observed following treatment with incobotulinumtoxinA. J Rehabil Med. 2020 Mar 18; 52(3):jrm00028.
Score: 0.658
-
Fheodoroff K, Rekand T, Medeiros L, Ko?mehl P, Wissel J, Bensmail D, Scheschonka A, Flatau-Baqu? B, Simon O, Dressler D, Simpson DM. Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA. Health Qual Life Outcomes. 2020 Mar 04; 18(1):51.
Score: 0.656
-
Esquenazi A, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Graham GD, McGuire JR, Odderson IR, Patel AT, Simpson DM. OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a?Delphi Panel Approach. PM R. 2017 Oct; 9(10):960-968.
Score: 0.533
-
Simpson DM, Patel AT, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Esquenazi A, Graham GD, McGuire JR, Odderson I. OnabotulinumtoxinA Injection for Poststroke Upper-Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process. PM R. 2017 02; 9(2):136-148.
Score: 0.508
-
Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10; 86(19):1818-26.
Score: 0.501
-
Kaku M, Simpson DM. Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity. Drug Des Devel Ther. 2016; 10:1085-99.
Score: 0.497
-
Brown EA, Sch?tz SG, Simpson DM. Botulinum toxin for neuropathic pain and spasticity: an overview. Pain Manag. 2014 Mar; 4(2):129-51.
Score: 0.432
-
Thomas AM, Simpson DM. Contralateral weakness following botulinum toxin for poststroke spasticity. Muscle Nerve. 2012 Sep; 46(3):443-8.
Score: 0.390
-
Simpson DM, Gracies JM, Graham K, Hallett M, Miyasaki J, Naumann M, Russman B, Simpson L, So Y. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Neurology. 2009 Sep 01; 73(9):736-7; author reply 737-8.
Score: 0.317
-
Burridge JH, Turk R, Notley SV, Pickering RM, Simpson DM. The relationship between upper limb activity and impairment in post-stroke hemiplegia. Disabil Rehabil. 2009; 31(2):109-17.
Score: 0.302
-
Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009 Jan; 90(1):9-16.e2.
Score: 0.302
-
Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009 Apr; 80(4):380-5.
Score: 0.299
-
Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 06; 70(19):1691-8.
Score: 0.289
-
O'Dell MW, Brashear A, Jech R, Lejeune T, Marque P, Bensmail D, Ayyoub Z, Simpson DM, Volteau M, Vilain C, Picaut P, Gracies JM. Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study. PM R. 2018 01; 10(1):1-10.
Score: 0.136
-
Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, Rekand T, McGuire J, Scheschonka A, Flatau-Baqu? B, Simon O, Rochford ET, Dressler D, Simpson DM. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study. Neurology. 2017 Apr 04; 88(14):1321-1328.
Score: 0.133
-
Gracies JM, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part I: Local treatments. Muscle Nerve Suppl. 1997; 6:S61-91.
Score: 0.132
-
Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl. 1997; 6:S92-120.
Score: 0.132
-
Simpson DM. Clinical trials of botulinum toxin in the treatment of spasticity. Muscle Nerve Suppl. 1997; 6:S169-75.
Score: 0.132
-
Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996 May; 46(5):1306-10.
Score: 0.126
-
Wissel J, Verrier M, Simpson DM, Charles D, Guinto P, Papapetropoulos S, Sunnerhagen KS. Post-stroke spasticity: predictors of early development and considerations for therapeutic intervention. PM R. 2015 Jan; 7(1):60-7.
Score: 0.112
-
Gracies JM, Bayle N, Goldberg S, Simpson DM. Botulinum toxin type B in the spastic arm: a randomized, double-blind, placebo-controlled, preliminary study. Arch Phys Med Rehabil. 2014 Jul; 95(7):1303-11.
Score: 0.109
-
Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal KR, Simpson DM, Smith CP, Ward AB. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon. 2013 Jun 01; 67:115-28.
Score: 0.099
-
Vinti M, Costantino F, Bayle N, Simpson DM, Weisz DJ, Gracies JM. Spastic cocontraction in hemiparesis: effects of botulinum toxin. Muscle Nerve. 2012 Dec; 46(6):926-31.
Score: 0.098
-
Dobkin BH, Landau WM, Sahrmann S, Thomas Thach W, Simpson DM, Gracies JM, Graham K, Hallett M, Miyasaki J, Naumann M, Russman B, Simpson L, So Y. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Neurology. 2009 Sep 01; 73(9):736; author reply 737-8.
Score: 0.079
-
Turk R, Notley SV, Pickering RM, Simpson DM, Wright PA, Burridge JH. Reliability and sensitivity of a wrist rig to measure motor control and spasticity in poststroke hemiplegia. Neurorehabil Neural Repair. 2008 Nov-Dec; 22(6):684-96.
Score: 0.074
-
Di Rocco A, Tagliati M, Danisi F, Dorfman D, Moise J, Simpson DM. A pilot study of L-methionine for the treatment of AIDS-associated myelopathy. Neurology. 1998 Jul; 51(1):266-8.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|